Equities research analysts at Robert W. Baird Upgraded shares of Cubist Pharmaceuticals, Inc. (CBST) to a “Outperform” rating in a research note released to investors today. Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the [...]
View Comments
04/05/2011 3:41 am PDT - Analysts Coverage